Drugs / Furosemide
Furosemide
also known as
Lasix · Frusemide · Furoscix · CLS006 · Lasix ONYU · Lasix, furosemide · SQINFurosemide · Furosemide Injection · +8 more
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | FUROSCIX | — | 2024-08-09 – 2026-07-23 | fda.gov ↗ |
| Approved | EU (EMA) | Bopediat | — | 2026-05-29 | europa.eu ↗ |
| Label expansions (2) | US (FDA) | LASIX | — | 1981-02-05 – 2007-12-07 | fda.gov ↗ |
| Approved | US (FDA) | LASIX | — | 1966-07-01 | fda.gov ↗ |
| Filed | US (FDA) | FUROSCIX ReadyFlow | heart failure, chronic kidney disease | — | “Additionally, the FUROSCIX ReadyFlow™ Autoinjector supplemental New Drug Application (sNDA) filing was submitted as planned in Q3 2025.” mannkindcorp.com ↗ “FUROSCIX ReadyFlow Autoinjector supplemental New Drug Application (sNDA) filing submitted as planned in Q3 2025” mannkindcorp.com ↗ |
Trials 180 · started per year
today
US approved 1966
EU approved 2026
1
1
1
3
1
6
2
2
5
4
6
4
5
5
5
15
14
11
9
6
12
12
4
13
12
7
12
19651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials | ||||||
| Phase 0 | NCT06821594 | Apr → Aug 2025 overdue | benign neoplasm of skin | Jinnah Postgraduate Medical Centre | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT05365451 | Apr 2022 → Jul 2023 | — | Washington State University | Completed | No outcome recorded |
| Phase 0 | NCT05098366 | May 2021 → Dec 2023 | — | Connecticut Children's Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT03837470 | May 2019 → Feb 2020 | diastolic heart failure | Adhish Agarwal | Completed | No outcome recorded |
| Phase 0 | NCT03772262 | Apr → Nov 2018 | — | Washington State University | Completed | No outcome recorded |
| Phase 0 | NCT03946891 | Jun 2016 → Jun 2023 | pulmonary immaturity | NYU Langone Health | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT02802696 | Jun 2016 → Mar 2017 | — | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 136 trials · 1 met primary · 1 missed | ||||||
| Phase 1 | NCT07431866 | Mar → Jun 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT07269496 | Feb → Mar 2026 | — | SQ Innovation, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT07073157 | Jul → Aug 2025 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06504862 | Aug → Oct 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06491550 | Jul 2024 → Jun 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06167707 | Apr → Jun 2024 | heart failure | scPharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05768360 | Apr → Jun 2023 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05981365 | Apr → Oct 2023 | sickle cell disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04850638 | Jun → Sep 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04846816 | May → Aug 2021 | heart failure | SQ Innovation, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04763226 | Apr 2021 → Feb 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04590937 | Oct 2020 → Jan 2021 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05105009 | Mar 2020 → Oct 2023 | chronic renal failure syndrome | Instituto Nacional de Cardiologia Ignacio Chavez | Completed | No outcome recorded |
| Phase 1 | NCT04233437 | Feb → May 2020 | stroke disorder | Moleac Pte Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04161482 | Dec 2019 → Jun 2020 | — | scPharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04481789 | Oct → Dec 2018 | — | Shionogi | Completed | No outcome recorded |
| Phase 1 | NCT03801759 | Jul → Sep 2018 | — | Akebia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT07173738 | Jun → Sep 2018 | pulmonary arterial hypertension | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT03307252 | Oct 2017 → May 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03103568 | Mar → Jun 2017 | — | Swedish Orphan Biovitrum | Completed | No outcome recorded |
| Phase 1 | NCT03010475 | Jan → Jun 2017 | diabetes mellitus | Novo Nordisk A/S | Completed | Missed primary |
| Phase 1 | NCT02877095 | Dec 2016 → Nov 2017 | heart failure | Adrian Hernandez | Completed | No outcome recorded |
| Phase 1 | NCT02854527 | Aug → Nov 2016 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01851980 | Apr 2016 → Apr 2017 | — | McGill University | Unknown | No outcome recorded |
| Phase 1 | NCT02574845 | Oct → Dec 2015 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02881866 | Oct 2015 → Mar 2016 | — | Oxford Brookes University | Completed | Mixed |
| Phase 1 | NCT02546583 | Aug 2015 → Jan 2020 | heart failure | Yale University | Completed | Met primary |
| Phase 1 | NCT02231931 | Sep 2014 → Jan 2015 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02028689 | Oct → Nov 2013 | — | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01887379 | Jun → Aug 2013 | — | LTS Lohmann Therapie-Systeme AG | Completed | No outcome recorded |
| Phase 1 | NCT01724788 | Nov 2012 → Jan 2013 | kidney failure | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01611415 | Jul → Oct 2011 | — | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 1 | NCT01438359 | Jul → Sep 2011 | — | Vifor Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01062776 | Oct 2009 → May 2010 | — | Sodertalje Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00671424 | Mar → May 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00261937 | Dec 2005 → Apr 2006 | bronchiolitis | Bnai Zion Medical Center | Completed | No outcome recorded |
| Phase 1/27 trials · 3 missed | ||||||
| Phase 1/2 | NCT06024889 | Sep 2023 → Feb 2024 | heart failure | Johannes Grand | Completed | Missed primary |
| Phase 1/2 | NCT04384653 | Oct 2020 → Jun 2021 | heart failure | SQ Innovation, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02721511 | May 2016 → Mar 2017 | heart failure | Todd M Koelling, MD | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02350725 | Dec 2014 → Jun 2015 | heart failure | scPharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02524054 | Nov 2014 → Nov 2016 | — | Beth Israel Deaconess Medical Center | Completed | Missed primary |
| Phase 1/2 | NCT01440764 | Sep 2011 → Apr 2016 | — | Beth Israel Deaconess Medical Center | Completed | Missed primary |
| Phase 1/2 | NCT00982423 | Jul 2009 → Jul 2014 | heart failure, impaired renal function disease | Mayo Clinic | Completed | No outcome recorded |
| Phase 225 trials · 3 missed | ||||||
| Phase 2 | NCT07648251 | Jun → Dec 2026 expected | severe pre-eclampsia | Universidad Nacional Autonoma de Honduras | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07307131 | Sep 2024 → Mar 2025 | common wart, human papilloma virus infection | Benha University | Completed | No outcome recorded |
| Phase 2 | NCT06326112 | May 2024 → Mar 2025 | acute respiratory distress syndrome, critical illness polyneuropathy, infectious disease with sepsis | Unity Health Toronto | Unknown | No outcome recorded |
| Phase 2 | NCT05528588 | Jun 2023 → Apr 2024 | heart failure | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT05779943 | Apr 2023 → Mar 2024 overdue | prostate adenocarcinoma | Emory University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04919564 | May → Dec 2021 | chronic kidney disease, heart disorder | National Cardiovascular Center Harapan Kita Hospital Indonesia | Completed | No outcome recorded |
| Phase 2 | NCT04593823 | May 2021 → Apr 2022 | heart failure | scPharmaceuticals, Inc. | Completed | Missed primary |
| Phase 2 | NCT04622709 | Oct 2020 → Jun 2021 | end stage renal failure | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT03684772 | Oct 2018 → Sep 2019 | actinic keratosis | Maruho Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03556761 | Jun 2018 → Dec 2019 | hypertension, pregnancy-induced | University of Pennsylvania | Completed | Mixed |
| Phase 2 | NCT03170219 | Apr → Sep 2018 | heart failure | Adrian Hernandez | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03259165 | Dec 2017 → Dec 2021 | heart failure, pulmonary edema | Indiana University | Terminated | No outcome recorded |
| Phase 2 | NCT03362515 | Dec 2017 → Apr 2022 | nasal cavity polyp | Thomas Jefferson University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03364842 | Nov → Dec 2017 | lung disorder | Cairo University | Completed | No outcome recorded |
| Phase 2 | NCT03334240 | Oct 2017 → Oct 2018 | anogenital human papillomavirus infection | Maruho Co., Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT04393493 | Jul 2017 → Apr 2020 | cardio-renal syndrome | Hospital Civil de Guadalajara | Completed | Missed primary |
| Phase 2 | NCT02804035 | Jul → Aug 2016 | heart failure | scPharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02527798 | Nov 2015 → Oct 2019 | bronchopulmonary dysplasia | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT02450773 | Aug 2015 → May 2022 | hypertensive disorder | Indiana University | Withdrawn | No outcome recorded |
| Phase 2 | NCT02333643 | Jan → Aug 2015 | benign neoplasm of skin | Maruho Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02821377 | Dec 2013 → Dec 2015 | cirrhosis of liver | University of Palermo | Completed | No outcome recorded |
| Phase 2 | NCT02469597 | Oct 2013 → Apr 2016 | bronchiolitis | Northwell Health | Completed | Missed primary |
| Phase 2 | NCT01407848 | Jan 2012 → Jul 2015 | persistent tachypnoe of infancy, usual | University of Cologne | Completed | No outcome recorded |
| Phase 2 | NCT01125514 | May 2010 → Aug 2011 | heart failure | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00624650 | Feb 2008 → Jan 2011 | acute lung injury | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 2/36 trials · 1 missed | ||||||
| Phase 2/3 | NCT06252454 | Feb → Dec 2024 | — | University Hospital Hradec Kralove | Unknown | No outcome recorded |
| Phase 2/3 | NCT05652322 | Dec 2022 → Dec 2023 | heart failure | Jan Kochanowski University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT04588792 | Apr 2021 → Feb 2023 | COVID-19, respiratory failure | Dr. John Muscedere | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT03359161 | Apr 2018 → Jan 2019 | heart failure | Steward St. Elizabeth's Medical Center of Boston, Inc. | Terminated | No outcome recorded |
| Phase 2/3 | NCT02579057 | Feb 2016 → Jun 2017 | congestive heart failure | Johns Hopkins University | Completed | Missed primary |
| Phase 2/3 | NCT02329834 | Apr → Oct 2015 | heart failure | scPharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 326 trials · 4 met primary · 5 missed | ||||||
| Phase 3 | NCT07018297 | Aug 2026 → Aug 2028 expected | heart failure | University of Texas Southwestern Medical Center | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06941415 | Jun 2026 → Mar 2029 expected | cirrhosis of liver | Stacy Johnson | Recruiting | No outcome recorded |
| Phase 3 | NCT07008365 | Mar 2025 → Nov 2026 expected | cardio-renal syndrome, congestive heart failure | Aragon Health Research Institute (IISAragon) | Recruiting | No outcome recorded |
| Phase 3 | NCT06407401 | Dec 2024 → Apr 2028 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, musculoskeletal system disorder | European Organisation for Research and Treatment of Cancer - EORTC | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05916963 | Jan 2024 → Apr 2026 overdue | urolithiasis | University Hospital, Tours | Recruiting | No outcome recorded |
| Phase 3 | NCT05620784 | Mar → Jun 2023 overdue | benign prostatic hyperplasia | Northwestern University | Recruiting | No outcome recorded |
| Phase 3 | NCT05769738 | Mar 2023 → Dec 2024 | chronic obstructive pulmonary disease | American University of Beirut Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT05962255 | Feb 2022 → Apr 2024 | heart failure | Wroclaw Medical University | Completed | Met primary |
| Phase 3 | NCT04752475 | Oct 2021 → Apr 2022 | preeclampsia | Columbia University | Completed | No outcome recorded |
| Phase 3 | NCT04706910 | Jan 2021 → Dec 2027 expected | Lewy body dementia, Parkinson disease, brain neoplasm, congenital isolated hyperinsulinism +2 | University of Alberta | Recruiting | No outcome recorded |
| Phase 3 | NCT04615624 | Jan 2021 → Apr 2022 | preeclampsia | Melanie Maykin, MD | Completed | Missed primary |
| Phase 3 | NCT03458325 | Nov 2020 → Jun 2021 | heart failure | scPharmaceuticals, Inc. | Completed | Met primary |
| Phase 3 | NCT05270421 | Jul 2020 → Mar 2022 | nephrolithiasis, ureterolithiasis | Shiraz University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT03259620 | Oct 2017 → Aug 2018 | common wart | Maruho Co., Ltd. | Completed | Missed primary |
| Phase 3 | NCT02971891 | Jan 2017 → Apr 2018 | common wart | Maruho Co., Ltd. | Completed | Missed primary |
| Phase 3 | NCT02905760 | Dec 2016 → Nov 2018 | acute myocardial infarction | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 3 | NCT03208894 | Nov 2016 → May 2017 | persistent tachypnoe of infancy, usual | Armed Forces Hospital, Pakistan | Completed | No outcome recorded |
| Phase 3 | NCT02804282 | Jul → Nov 2016 | heart failure | scPharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02345681 | May 2015 → Apr 2019 | — | Nantes University Hospital | Completed | Met primary |
| Phase 3 | NCT02417883 | Apr 2015 → Apr 2016 | chronic kidney disease | Instituto Nacional de Cardiologia Ignacio Chavez | Unknown | No outcome recorded |
| Phase 3 | NCT01028170 | Nov 2009 → Jul 2011 | congestive heart failure, impaired renal function disease | Aspirus Heart and Vascular Institute-Research and Education | Completed | No outcome recorded |
| Phase 3 | NCT00702728 | Jun 2008 → Jun 2009 | acute tubulointerstitial nephritis | Centro Cardiologico Monzino | Unknown | Met primary |
| Phase 3 | NCT00577135 | Feb 2008 → Jan 2010 | heart failure | Duke University | Completed | Missed primary |
| Phase 3 | NCT00618852 | Jan 2007 → Dec 2008 | lung disorder | The Hospital for Sick Children | Unknown | No outcome recorded |
| Phase 3 | NCT00298454 | Dec 2005 → Apr 2007 | kidney failure | Frisius Medisch Centrum | Terminated | Missed primary |
| Phase 3 | NCT00512811 | — | bronchiolitis | Baqiyatallah Medical Sciences University | Completed | No outcome recorded |
| Phase 433 trials · 3 met primary · 3 missed | ||||||
| Phase 4 | NCT07577596 | Jun 2026 → Sep 2027 expected | heart failure | University of Aarhus | Recruiting | No outcome recorded |
| Phase 4 | NCT07167862 | Jun 2026 → Jun 2028 expected | preeclampsia | University of California, Irvine | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06979726 | Nov 2025 → Nov 2026 expected | heart failure | University of Florida | Recruiting | No outcome recorded |
| Phase 4 | NCT06094816 | Mar 2024 → Jan 2028 expected | — | University of Delaware | Recruiting | No outcome recorded |
| Phase 4 | NCT06229990 | Jan 2024 → Dec 2028 expected | acute kidney injury | Chiang Mai University | Recruiting | No outcome recorded |
| Phase 4 | NCT05898022 | Aug 2023 → Jul 2025 | bronchopulmonary dysplasia | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 4 | NCT05915286 | May 2023 → Feb 2025 | end stage renal failure | University of Alberta | Terminated | No outcome recorded |
| Phase 4 | NCT05171686 | Feb 2023 → Oct 2025 | chronic kidney disease, hypertensive disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT05158153 | Oct 2021 → Apr 2022 | acute hypotension, acute kidney injury | University of California, San Francisco | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04192110 | Aug 2020 | chronic kidney disease | VA Office of Research and Development | Withdrawn | No outcome recorded |
| Phase 4 | NCT04343235 | May 2020 → Jun 2022 | hypertension, pregnancy-induced | Wright State University | Terminated | Missed primary Stop: Enrollment |
| Phase 4 | NCT03731117 | Jul 2019 → Dec 2020 | acute kidney injury | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 4 | NCT03892148 | May 2019 → Jan 2023 | heart failure | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 4 | NCT02960412 | May 2017 → Mar 2018 | — | University of South Florida | Completed | Met primary |
| Phase 4 | NCT02531581 | Dec 2015 → Apr 2020 | pulmonary embolism | Centre Hospitalier Universitaire de Nice | Completed | Missed primary |
| Phase 4 | NCT02458157 | Oct 2015 → Jun 2017 | acute kidney injury | Nordsjaellands Hospital | Terminated | Met primary Stop: Enrollment |
| Phase 4 | NCT02832973 | Sep 2015 → Dec 2017 | resistant hypertension | Sao Jose do Rio Preto Medical School | Completed | No outcome recorded |
| Phase 4 | NCT02539810 | Sep 2015 → Dec 2016 | renal artery atheroma, resistant hypertension | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 4 | NCT02351934 | Feb 2015 → Apr 2016 | large intestine disorder | Mayo Clinic | Completed | Missed primary |
| Phase 4 | NCT02643147 | Jan 2015 → Jan 2017 | heart failure | Fundación para la Investigación del Hospital Clínico de Valencia | Completed | No outcome recorded |
| Phase 4 | NCT02163655 | Jun → Nov 2014 | severe pre-eclampsia | Instituto Materno Infantil Prof. Fernando Figueira | Completed | No outcome recorded |
| Phase 4 | NCT01977430 | Nov 2013 → Mar 2015 | chronic kidney disease | Corporacion Parc Tauli | Unknown | No outcome recorded |
| Phase 4 | NCT04691687 | May 2012 → Dec 2017 | heart failure | New York Presbyterian Brooklyn Methodist Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01156220 | Jan → Jun 2012 | — | University Medical Center Hamburg-Eppendorf | Withdrawn | No outcome recorded |
| Phase 4 | NCT01441245 | Apr 2010 → Jun 2016 | heart failure | University of Siena | Completed | Mixed |
| Phase 4 | NCT00535925 | Oct 2005 → Dec 2011 | diabetic kidney disease | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT00478543 | Sep 2005 → May 2008 | chronic kidney disease | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT00741663 | Apr 2005 → Sep 2008 | cirrhosis of liver | University of Padova | Completed | No outcome recorded |
| Phase 4 | NCT00200694 | Mar 2005 → Mar 2007 | proteinuria | Nantes University Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00664222 | Jan 2004 → Dec 2005 | heart failure | Tottori University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00652652 | Mar 2003 → Jan 2004 | congestive heart failure | Scios, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00306696 | Oct 2002 → Jan 2004 | diabetes mellitus | GlaxoSmithKline | Completed | Met primary |
| Phase 4 | NCT00115726 | Sep 2000 → Feb 2006 | congestive heart failure, hypertensive disorder, hypotensive disorder | University of Calgary | Completed | No outcome recorded |
| Phase not applicable40 trials · 1 met primary · 4 missed | ||||||
| — | NCT07861685 | Oct 2026 → Mar 2027 expected | severe pre-eclampsia | Lady Reading Hospital, Pakistan | Recruiting | No outcome recorded |
| — | NCT07550790 | Jul 2026 → Jun 2027 expected | heart failure, impaired renal function disease | Jin Joo Park | Recruiting | No outcome recorded |
| — | NCT07631780 | Jun 2026 → Dec 2027 expected | symptomatic heart failure | Nurgul Ablakimova | Not yet recruiting | No outcome recorded |
| — | NCT07348510 | Jan → Jul 2026 overdue | — | Cairo University | Recruiting | No outcome recorded |
| — | NCT07804654 | Jan → Jul 2026 | heart failure | Universiti Teknologi Mara | Completed | No outcome recorded |
| — | NCT07077772 | Jun 2025 → Oct 2027 expected | — | Centre Hospitalier Universitaire, Amiens | Recruiting | No outcome recorded |
| — | NCT07417969 | Jun 2025 → Sep 2026 overdue | anuria | Jose J Zaragoza, MD MSc | Recruiting | No outcome recorded |
| — | NCT07336485 | Jan → Jul 2025 | nephrolithiasis | Ain Shams University | Completed | No outcome recorded |
| — | NCT06765031 | Nov 2024 → Mar 2026 overdue | acute kidney injury | Gulhane Training and Research Hospital | Recruiting | No outcome recorded |
| — | NCT07464249 | Apr → Sep 2024 | heart failure | Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey | Completed | No outcome recorded |
| — | NCT05741372 | Sep 2023 → Dec 2024 | cirrhosis of liver | Boehringer Ingelheim | Completed | No outcome recorded |
| — | NCT05939193 | Jul 2023 → Jul 2024 | acute kidney injury | Peking University First Hospital | Completed | No outcome recorded |
| — | NCT05440851 | Apr 2023 → Mar 2027 expected | respiratory failure | University Health Network, Toronto | Recruiting | No outcome recorded |
| — | NCT06710600 | Sep 2022 → Apr 2024 | photosensitivity disease | Medical University of Vienna | Completed | No outcome recorded |
| — | NCT06097923 | Nov 2021 → Dec 2022 | — | Seoul St. Mary's Hospital | Completed | Missed primary |
| — | NCT04170855 | Oct 2020 → Dec 2026 expected | cardio-renal syndrome | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Active not recruiting | No outcome recorded |
| — | NCT04235062 | Apr 2020 → Apr 2021 | heart failure | Momentum Research, Inc. | Completed | No outcome recorded |
| — | NCT05379257 | Jan 2020 → Dec 2022 | congestive heart failure | Hadassah Medical Organization | Unknown | No outcome recorded |
| — | NCT04182854 | Oct 2019 → Feb 2020 | antidepressant type abuse | Capital Medical University | Unknown | No outcome recorded |
| — | NCT07568886 | Apr 2019 → Apr 2023 | ovarian hyperstimulation syndrome | Al-Nahrain University | Completed | No outcome recorded |
| — | NCT03613779 | Apr 2018 → Dec 2019 | heart failure | Instituto Nacional de Cardiologia Ignacio Chavez | Completed | No outcome recorded |
| — | NCT03071536 | Nov 2016 → May 2026 overdue | impaired renal function disease | King Chulalongkorn Memorial Hospital | Recruiting | No outcome recorded |
| — | NCT02765009 | Jun 2016 → Jul 2019 | — | Central Hospital, Nancy, France | Completed | Missed primary |
| — | NCT02800135 | Apr 2016 → Mar 2018 | — | University Hospital of Saint-Etienne | Terminated | No outcome recorded |
| — | NCT02047422 | Jan 2014 → Feb 2016 | congestive heart failure | Yonsei University | Withdrawn | No outcome recorded |
| — | NCT01705470 | Oct 2012 → Jun 2013 | aregenerative anemia | Tel-Aviv Sourasky Medical Center | Withdrawn | No outcome recorded |
| — | NCT01709227 | Oct 2011 → Jun 2015 | acute kidney injury | Children's Hospital Medical Center, Cincinnati | Completed | Missed primary |
| — | NCT01275729 | Dec 2010 → Jun 2022 | acute kidney injury | University of Chicago | Completed | No outcome recorded |
| — | NCT01320007 | Sep 2010 → Oct 2014 | heart failure | Barts & The London NHS Trust | Completed | No outcome recorded |
| — | NCT01146288 | Jul 2010 → May 2014 | medulloadrenal hyperfunction | Rabin Medical Center | Completed | Met primary |
| — | NCT01072071 | Feb 2010 → Dec 2011 | — | Ziekenhuis Netwerk Antwerpen (ZNA) | Unknown | No outcome recorded |
| — | NCT00962286 | Sep 2009 → May 2010 | medulloadrenal hyperfunction | Rabin Medical Center | Terminated | No outcome recorded |
| — | NCT00673244 | Apr 2008 → Dec 2013 | acute kidney injury | George Washington University | Completed | No outcome recorded |
| — | NCT00531908 | Sep 2007 → Dec 2009 | acromegaly | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT00429897 | Aug 2006 → Jul 2007 | hypertensive disorder | University of Cambridge | Unknown | No outcome recorded |
| — | NCT00285805 | Feb → Oct 2006 | — | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT00240019 | Dec 2003 → Apr 2006 | diabetic kidney disease | Stanford University | Completed | No outcome recorded |
| — | NCT00141596 | Jul 2003 → Oct 2006 | hypertensive disorder | St George's, University of London | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00175227 | May 1996 → Oct 2000 | acute kidney injury, chronic kidney disease | University of Alberta | Completed | Missed primary |
| — | NCT00246675 | — | cardio-renal syndrome | Melbourne Health | Withdrawn | No outcome recorded Stop: Enrollment |
| Comparator or background therapy120 trials | ||||||
| Phase 0 | NCT02983422 Comparator | Dec 2016 → Jun 2017 | acute kidney injury | Shanghai Jiao Tong University Affiliated Sixth People's Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT06899061 Comparator | Mar 2025 → Feb 2026 overdue | high grade malignant neoplasm | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05470283 Background | Sep 2022 → Apr 2027 expected | metastatic melanoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03509545 Comparator | Jun 2021 → Jun 2022 | — | Sarfez Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04130815 Comparator | Oct 2019 → Sep 2020 | — | Oxford Brookes University | Unknown | No outcome recorded |
| Show all 120 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2026-10-09 | Mannkind Corporation | Results MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) mannkindcorp.com ↗
New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemide |
| 2026-07-24 | Mannkind Corporation | Regulatory MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease mannkindcorp.com ↗
MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Furoscix ReadyFlow™ (furosemide injection) for the treatment of edema (fluid overload) in adults with heart failure (HF) or chronic kidney disease (CKD). |
| 2026-02-26 | Mannkind Corporation | Regulatory MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update mannkindcorp.com ↗
FDA accepted for review a supplemental New Drug Application (sNDA) for Furoscix ReadyFlow Autoinjector |
| 2025-12-23 | Mannkind Corporation | Regulatory MannKind Shares FUROSCIX® Business Updates mannkindcorp.com ↗
The U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for FUROSCIX® (furosemide) On-body Infusor, expanding the indication of this product to include pediatric patients weighing 43 kg or more. |
| 2025-12-01 | Mannkind Corporation | Regulatory MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease mannkindcorp.com ↗
The application has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 26, 2026. |
| 2025-10-09 | Ligand Pharmaceuticals | Regulatory Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients ligand.com ↗ |
| 2025-10-08 | SQ Innovation, Inc. | Regulatory SQ Innovation Announces FDA Approval of Lasix® ONYU for Treatment of Edema in Heart Failure sqinnovation.com ↗
SQ Innovation, Inc . today announced that the U.S. Food and Drug Administration (FDA) has approved its drug-device combination Lasix ® ONYU (furosemide injection) for the treatment of edema (due to fluid overload) in adult patients with chronic heart failure. |
| 2024-06-10 | Blue Earth Diagnostics | Results Blue Earth Diagnostics Highlights Results of Studies Evaluating Impact of Urinary Activity on Image Interpretation and Performance of POSLUMA® (Flotufolastat F 18) and 18F-Flotufolastat PET in Prostate Cancer blueearthdiagnostics.com ↗ |
| 2012-09-04 | Trevena Inc. | Results Trevena Acute Heart Failure Drug TRV027 Unloads the Heart and Maintains Renal Function When Co-administered with Furosemide in Dog Heart Failure Model trevena.com ↗
These findings indicate that TRV027 may work additively or synergistically with loop diuretics like furosemide, which are current standard of care for treating acute heart failure. |
All press releases naming this drug 12 releases
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 302 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FUROSEMIDE | “The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide,...” NCT04192110 ↗289“A Phase 2, Randomized, Vehicle-controlled, Double-blind Study to Explore the Efficacy, Pharmacodynamics and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of...” NCT03334240 ↗ “Patients were randomized to receive either usual care, including conventional optimal treatment with furosemide, oxygen, and high-dose boluses of isosorbide dinitrate plus...” PMID 20825901 ↗ May 2010 “Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker (irbesartan 300mg), a diuretic (furosemide 40mg or indapamide LP 1.5mg according to the...” NCT01588795 ↗ “Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered...” NCT04593823 ↗ “Furoscix (furosemide injection 8 mg/ml), is a furosemide solution buffered to a neutral pH containing 80 mg/10 mL for subcutaneous administration over 5 hours via the Furoscix Infusor.” NCT03458325 ↗ “Lung ultrasound guided therapy; if pulmonary congestion (more or equal than 3 B-lines), high dose (80-120mg PO/day furosemide) will be prescribed until next follow up re-assessment.” NCT03613779 ↗ “In cases where the patient was not previously on oral diuretics, a starting dose of 40 mg of IV furosemide, IV bumetanide 1 mg or a bolus of 20 mg of IV torsemide can be utilized.” NCT06414759 ↗ “Furosemide: Nebulized furosemide has been studied as a potential treatment option for ARDS patients due to its diuretic properties and potential to reduce pulmonary edema.” NCT07286409 ↗ “including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.” NCT03180450 ↗ “The patients in this arm will be randomized to receiving oral furosemide in 2 daily divided doses at twice the intravenous dose administered during the past 24 hours.” NCT04062760 ↗ |
| Known as | CLS006 | “Furosemide Topical Gel 0.125% (CLS006)” NCT03259620 ↗1“CLS006 (Furosemide) Topical Gel” NCT02971891 ↗ |
| Known as | Frusemide | “Hydration of patient with 0.5L NaCl and 20mg frusemide IV” NCT01852669 ↗ |
| Known as | Furoscix | “The study drug, Furoscix (furosemide injection 8 mg/ml), is a furosemide solution buffered to a neutral pH containing 80 mg/10 mL for subcutaneous administration over 5 hours...” NCT03458325 ↗3“The study drug, Furoscix (furosemide injection 8 mg/ml), is a furosemide solution buffered to a neutral pH containing 80 mg/10 mL for subcutaneous administration over 5 hours...” NCT04593823 ↗ “Study Drug: Furoscix®, (Furosemide Injection), 80 mg/10 mL is a proprietary furosemide formulation” NCT05528588 ↗ “Furoscix 80 mg will be administered as a subcutaneous infusion.” NCT04161482 ↗ |
| Known as | Furosemide Injection | “Study Drug: Furoscix®, (Furosemide Injection), 80 mg/10 mL is a proprietary furosemide formulation” NCT05528588 ↗ |
| Known as | Furosemide Injection Solution | “The test formulation in this study is a buffered solution, Furosemide Injection Solution at 8 mg/mL at pH 7.4 (range 7.0 to 7.8) and is intended for SC injection according to...” NCT02329834 ↗ |
| Known as | Furosemide Injection Solution (SCP-101) | “Patients will be randomized to receive Furosemide Injection, USP intravenously or Furosemide Injection Solution (SCP-101) delivered subcutaneously.” NCT02579057 ↗ |
| Known as | Furosemide Injection, USP | “Furosemide Injection, USP (10mg/mL), 80 mg by intravenous administration.” NCT02329834 ↗ |
| Known as | Furosemide USP | “Drug: Furosemide USP” NCT06167707 ↗ |
| Known as | Furosemide: Seguril | “Furosemide: Seguril” NCT00409942 ↗ |
| Known as | HOE058 | “Drug: FUROSEMIDE (HOE058)” NCT01724788 ↗ |
| Known as | Lasix | “Furosemide (Lasix) is frequently administered to patients with acutely decompensated heart failure to relieve pulmonary vascular congestion and promote diuresis.” NCT00652652 ↗10“Furosemide (Lasix, 20 mg) will be administered through IV catheter to induce urination.” NCT06467825 ↗ “Cohort 1 will receive furosemide (Lasix) 40 to 80 mg IVP BID for at least 48 hours” NCT04216784 ↗ “Placebo Comparator: Control-- furosemide (lasix) only” NCT01617798 ↗ “the other one will receive furosemide 40 mg (Lasix®)” NCT01210365 ↗ “Intervention: drug: furosemide ; other name: lasix” NCT02821377 ↗ “to a maximum of 8mg IV Bumex (or 320mg IV Lasix).” NCT04572867 ↗ “Furosemide (Lasix), 20 milligram, PO, PO, daily” NCT03556761 ↗ “furosemide (Lasix) 40mg” NCT06710600 ↗ |
| Known as | Lasix (Sanofi-Aventis) | “Lasix (Sanofi-Aventis)” NCT01072071 ↗ |
| Known as | Lasix ONYU | “The investigators will conduct an open-label, non-comparative, real-world study to evaluate the effectiveness and feasibility of at-home decongestion treatment using Lasix ONYU...” NCT06979726 ↗1“prefilled units of Lasix® ONYU furosemide injection containing 80 mg per 2.67 mL” NCT07018297 ↗ |
| Known as | Lasix, furosemide | “Lasix (Furosemide)” NCT02646540 ↗1“Lasix, furosemide” NCT01457053 ↗ |
| Known as | SCP-111 | “Subcutaneous Injection of SCP-111 (Furosemide) vs Intravenous Injection of Furosemide in Healthy Volunteers” NCT06167707 ↗ |
| Known as | SQINFurosemide | “SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.” NCT04846816 ↗1“SQIN-Furosemide is a novel formulation of furosemide at 30mg/mL at pH 7.5 (range 7.1 to 7.8) intended for subcutaneous use.” NCT07269496 ↗ |
| Action | Inhibit | “25 mg furosemide (a Na-K-2Cl cotransporter blocker)” PMID 21508131 ↗ Apr 2011 |
| Modality | Other / unclassified | “two standard of care loop diuretics (furosemide versus torsemide)” NCT05093621 ↗ |
| Route | Oral | “Furosemide oral tablets” NCT00151827 ↗ |